Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $55

Benzinga Newsdesk www.benzinga.com Negative 91.2%

Neg 91.2% Neu 0% Pos 0%

Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $62 to $55.